3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
86
Ovarian Neoplasms
33
Breast Neoplasms
29
Carcinoma, Non-Small-Cell Lung
28
Colonic Neoplasms
23
Rectal Neoplasms
21
Fallopian Tube Neoplasms
17
Neoplasms
16
Neoplasm Metastasis
13
Carcinoma, Hepatocellular
13
Glioblastoma
11
Lung Neoplasms
10
Brain Neoplasms
8
Carcinoma, Renal Cell
7
Uterine Cervical Neoplasms
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Intestinal Neoplasms
5
Gastrointestinal Neoplasms
5
Digestive System Neoplasms
5
Brenner Tumor
5
Recurrence
4
Peritoneal Neoplasms
4
Glioma
4
Carcinoma, Ovarian Epithelial
4
Adenocarcinoma of Lung
4
Rectal Diseases
3
Non-Squamous Non-Small Cell Lung Cancer
3
Liver Neoplasms
3
Intestinal Diseases
3
Gastrointestinal Diseases
3
Interventions
Imatinib Mesylate
19
Sunitinib
9
nilotinib
4
ripretinib
3
regorafenib
2
masitinib
2
tanespimycin
1
famitinib
1
avapritinib
1
Sodium Chloride
1
Midazolam
1
Mastectomy, Segmental
1
Immunoglobulin G
1
IDRX-42
1
Fentanyl
1
Disulfides
1
Carnitine
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Gastrointestinal Stromal Tumors
×
Bevacizumab
×
Clear all
NCT00324987
2017-09-14
S0502
National Cancer Institute (NCI)
Phase 3
Terminated
12 enrolled
13 charts